Hefiya

Hefiya is a biologic medication that contains the active ingredient adalimumab, a fully human monoclonal antibody supplied as a sterile solution for subcutaneous injection. It is marketed in the European Union and classified as a disease‑modifying anti‑rheumatic drug (DMARD). The product is intended for the treatment of certain chronic inflammatory conditions and may be prescribed as part of a comprehensive management plan.

Hefiya is indicated for the management of several immune‑mediated inflammatory disorders where inhibition of tumor necrosis factor‑α (TNF‑α) is beneficial.

- Moderate to severe rheumatoid arthritis in adults who have had an inadequate response to conventional disease‑modifying antirheumatic drugs (DMARDs). - Active psoriatic arthritis, including peripheral joint disease and axial involvement. - Moderate to severe plaque psoriasis that is unsuitable for topical therapy alone. - Ankylosing spondylitis and non‑radiographic axial spondyloarthritis. - Crohn’s disease in adults with moderate to severe activity. - Ulcerative colitis in adults with moderate to severe disease.

The safety profile of Hefiya reflects the pharmacology of adalimumab, a TNF‑α inhibitor, and includes both common and less frequent serious reactions.

Common: - Injection site reactions such as redness, swelling, itching, or mild pain that usually resolve within a few days. - Upper respiratory tract infections, including sinusitis, nasopharyngitis, or mild bronchitis. - Headache, often described as mild to moderate intensity. - Nausea or transient gastrointestinal discomfort.

Serious: - Serious infections, for example tuberculosis, bacterial sepsis, opportunistic fungal infections, or viral infections such as herpes zoster. - Reactivation of hepatitis B virus in patients with prior exposure. - Malignancies, including lymphoma, solid tumors, or non‑melanoma skin cancers. - New onset or worsening congestive heart failure. - Demyelinating disorders such as multiple sclerosis‑like events.

When prescribing Hefiya, clinicians should evaluate patient history and monitor for conditions that could increase risk during therapy.

- Screen for active or latent tuberculosis before initiating treatment and repeat monitoring as clinically indicated. - Assess for chronic or recurrent infections, including hepatitis B and C status. - Evaluate for a history of malignancy, particularly lymphoproliferative disorders. - Review cardiac function; avoid use in patients with moderate to severe heart failure. - Consider vaccination status; administer necessary vaccines prior to starting therapy. - Use caution in pregnant or breastfeeding women; discuss potential risks and benefits.

Adalimumab may interact with other medicines that affect the immune system or increase infection risk.

Avoid: - Live vaccines administered during treatment, as the immunosuppressive effect can reduce vaccine efficacy and increase adverse events. - Concurrent use of other biologic disease‑modifying agents (e.g., abatacept, rituximab) due to heightened immunosuppression. - Combination with JAK inhibitors (e.g., tofacitinib) should be avoided due to overlapping immunosuppressive mechanisms.

Use with caution: - Systemic corticosteroids, which may augment infection risk. - Immunosuppressive agents such as methotrexate or azathioprine, requiring close monitoring. - Antiviral therapies for hepatitis B, as reactivation can occur. - Concomitant use of interferon‑beta in multiple sclerosis patients. - Concurrent use of NSAIDs may increase risk of infection and should be monitored.